Opendata, web and dolomites


High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Total Cost €


EC-Contrib. €






 TUMOURPRINT project word cloud

Explore the words cloud of the TUMOURPRINT project. It provides you a very rough idea of what is the project "TUMOURPRINT" about.

live    drug    failed    animal    attrition    vascularity    exasperatingly    clinical    ten    unsatisfactory    global    fabricating    combination    fidel    implications    mono    proven    human    world    2016    3d    models    principally    rely    pay    analytical    mimicking    robotics    designed    collaborations    constructs    specially    drive    pharmaceutical    track    tumourprint    countries    secured    completely    revolutionise    formulated    size    instructive    bioink    capacity    commercialised    universal    organisation    bioprinters    cultures    generations    automated    ing    willingness    producing    serial    proposition    optimal    trials    platform    predict    tissue    2d    tumour    none    market    first    heterogeneity    cell    oncology    economic    bioprinting    reproducible    fold    establishment    grown    cancer    microenvironment    18    rates    scoring    survival    printing    humans    bioinks    ethically    precise    cells    hydrogels    printed    throughput    commercialise    giants    constitutes    commercialized    offers    outcomes    environment    destructive    record    disruptive    company    candidates    commercialising    proper    cellink    unparalleled    successfully   

Project "TUMOURPRINT" data sheet

The following table provides information about the project.


Organization address
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website
 Total cost 3˙500˙467 €
 EC max contribution 2˙450˙327 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2021-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLINK AB SE (GOTEBORG) coordinator 2˙450˙327.00


 Project objective

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).

The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.

CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.


List of deliverables.
Cancer cell lines selected Documents, reports 2019-11-28 17:30:38
10 hired employees Demonstrators, pilots, prototypes 2019-11-28 17:30:39

Take a look to the deliverables list in detail:  detailed list of TUMOURPRINT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUMOURPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUMOURPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More